Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1–MEK–Mitogen-Activated Protein Kinase Signalling Pathway
Theodor W. Schulte(American University), Leonard Μ. Neckers(National Cancer Institute), Joseph F. Johnston(Ionis Pharmaceuticals (United States)), J. Frederic Mushinski(National Cancer Institute), Mikhail V. Blagosklonny(Roswell Park Comprehensive Cancer Center), L.Y. Romanova(National Cancer Institute), Jane B. Trepel(National Institutes of Health), Phuongmai Nguyen(Cancer Institute (WIA)), Brett P. Monia(Ionis Pharmaceuticals (United States))
Cited by 275
Related Papers
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k